Skip to main content

SS-31 (Elamipretide) vs Hexarelin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

Hexarelin

Hexarelin is a potent synthetic hexapeptide growth hormone secretagogue. It provides the strongest GH release among GHRPs but is associated with rapid desensitization of receptors.

Full details →

Side-by-Side Comparison

AspectSS-31 (Elamipretide)Hexarelin
MechanismConcentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.Acts as a ghrelin mimetic with high potency at the GHS receptor. Provides powerful GH release but receptor desensitization occurs faster than with other GHRPs, requiring cycling.
Typical DosageClinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.Typical dosing: 100-200mcg administered 2-3 times daily for 4-6 weeks, followed by an equal off period to allow receptor resensitization.
AdministrationCan be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.Subcutaneous injection. Cycling is essential to maintain effectiveness. Often used in short bursts rather than continuous protocols.
Side EffectsGenerally well-tolerated. Clinical trials reported injection site reactions and occasional headache.Water retention, cortisol and prolactin increase, hunger (moderate), tingling, and potential blood pressure effects.
Best For

What They Have in Common

Both SS-31 (Elamipretide) and Hexarelin are commonly used for:

Key Differences

Unique to SS-31 (Elamipretide):

Unique to Hexarelin:

Ready to Learn More?